Israeli Life Science Company IOPtima Raises $7.2M

BioLight Life Sciences Investments, which is the parent company of IOPtima, an Israeli life science company, signed a joint financing agreement with two Asia-based venture capital firms in order for them to invest $7.2 million into IOPtima. The new funding will be used to empower the global commercialization of its innovative IOPtimate system, which is used in the treatment of glaucoma. 

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More